This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
by Sundeep Ganoria
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
by Sundeep Ganoria
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney
by Zacks Equity Research
GOOGL, ABBV, and DIS face rising costs and competition, but strong cloud, immunology, and parks growth continue to fuel optimism.
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
by Kinjel Shah
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
by Sundeep Ganoria
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
Top Stock Reports for Alphabet, AbbVie & Walt Disney
by Mark Vickery
GOOGL, ABBV, and DIS face distinct headwinds, but cloud strength, immunology growth, and parks momentum support long-term investor interest.
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
by Zacks Equity Research
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
by Kinjel Shah
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
by Kinjel Shah
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Here's Why AbbVie (ABBV) Fell More Than Broader Market
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
by Zacks Equity Research
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Here's Why AbbVie (ABBV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.